Patent ID: 7541029
Filing Date: 2009-06-02
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating or preventing Rhesus alloimmunization of Rh-negative individuals comprising administering to an Rh-negative individual in need thereof an anti-Rh(D) monoclonal antibody, wherein said monoclonal antibody exhibits a FcγRTIII-type ADCC level greater than 80% relative to a reference polyclonal anti-Rh(D) human antibody and wherein the monoclonal antibody has on Fcγ glycosylation site, Asn 297, EU numbering, a short chain bi-antennary glycan structure, with a low degree of sialylation and non-intercalated terminal mannose and non-intercalated terminal N-acetylglucosamines, wherein the monoclonal antibody has a content greater than 60% for the G0+G1+G0F +G1F forms, and wherein said glycan structure of the monoclonal antibody is selected from the group consisting of: and wherein the G0F+G1F forms are less than 50%.